Ziprasidone for Dementia in Elderly Patients: Case Review

Journal of Psychiatric Practice

Volumn 9, Issue 6, 2003, Pages 469-473

  Berkowitz, Alan ^a,b  

^a Psychiatric Centers at San Diego   (United States)

^b NONE   (United States)

Author keywords

Atypical antipsychotics; Cognitive symptoms; Dementia; Depression; Elderly; Postural hypotension; QTc interval; Ziprasidone

Indexed keywords

MIRTAZAPINE; NEFAZODONE; OLANZAPINE; OXCARBAZEPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SERTRALINE; VALPROATE SEMISODIUM; VENLAFAXINE; ZIPRASIDONE;

AGED; AUDITORY HALLUCINATION; BEHAVIOR DISORDER; CASE REPORT; CLINICAL FEATURE; DEMENTIA; DEPRESSION; DROWSINESS; DRUG INDICATION; ELDERLY CARE; ELECTROCARDIOGRAM; ELECTROCONVULSIVE THERAPY; FEMALE; FOLLOW UP; HUMAN; MALE; NURSING HOME; ORTHOSTATIC HYPOTENSION; PARANOIA; POLYPHARMACY; PSYCHOPHARMACOTHERAPY; QT INTERVAL; REVIEW; SEDATION; SIDE EFFECT; SYNCOPE; VERTIGO;

EID: 0345599220     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200311000-00011     Document Type: Review

References (20)

1. Conn DK, Lieff S. Diagnosing and managing delirium in the elderly. Can Fam Physician 2001;47:101-8.
2. Lipowski ZJ. Delirium (acute confusional states). JAMA 1987;258:1789-92.
3. Patkar AA, Kunkel EJ. Treating delirium in elderly patients. Psychiatr Serv 1997;48:46-8.
4. Schneider LS, Pollack VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatric Society 1990;38:553-63.
5. Glassman AH, Bigger JT. Antipsychotic drugs: Prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158:1774-82.
6. Allison DB, Mentore JL, Moonseong H, et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96.
7. Timar O, Sestier F, Levy E. Metabolic syndrome X: A review. Can J Cardiol 2000;16:779-89.
8. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765-74.
9. Risperdal® Prescribing Information. Titusville, NJ: Janssen Pharmaceutical Products, LP; 2003.
10. Lemmens P, Brecher M, Van Baelen B. A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: Factors associated with extrapyramidal symptoms. Acta Psychiatr Scand 1999;99:160-70.
11. Kwong K, Cavazzoni P, Hornbuckle K, et al. Higher incidences of diabetes mellitus during exposure to antipsychotics-findings from a retrospective cohort study in the US. Poster presented at the 41st Annual New Clinical Drug Evaluation Unit Meeting, May 28-31, 2002, Phoenix, AZ.
12. Arató M, O'Connor R, Bradbury JE, et al. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: The Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002;17:207-15.
13. Harvey PD, Meltzer H, Simpson GM, et al. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res; in press.
14. Harvey PD, Loebel A, Simpson GM. Ziprasidone vs olanzapine for cognitive function in schizophrenia. Poster presented at the 41st Annual Meeting of the American College of Neuropsychopharmacology, December 8-12, 2002, San Juan, Puerto Rico.
15. Glick ID, Romano SJ, Simpson G, et al. Insulin resistance in olanzapine- and ziprasidone-treated patients: Results of a double-blind, controlled 6-week trial. Poster presented at the 2001 International Congress on Schizophrenia Research, April 29-May 2, 2001, Whistler, British Columbia, Canada.
16. Cutler N, Simpson GM, Weiden PJ, et al. Effects of oral ziprasidone on weight and serum lipids in patients with schizophrenia. Poster presented at the 11th Biennial Winter Workshop on Schizophrenia, February 24-March 1, 2002, Davos, Switzerland.
17. Weiden PJ, Daniel DG, Simpson G, et al. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 2003;23:595-600.
18. Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003;54:565-7.
19. Geodon® Prescribing Information. New York, NY: Pfizer Inc; 2002.
20. Romano SJ. Cardiovascular safety profile of ziprasidone: Review of clinical development data. Poster presented at 154th Annual Meeting of the American Psychiatric Association; May 8, 2001; New Orleans, LA.